Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 10, 2006, Pages 1079-1083

  Worthley, Daniel L ^a,c   Smith, Alicia ^a,b   Bampton, Peter A ^a   Cole, Stephen R ^a,b   Young, Graeme P ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Colonic neoplasms; Mass screening; Occult blood; Patient participation

Indexed keywords

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RECTUM HEMORRHAGE;

AGED; ALGORITHMS; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PRACTICE GUIDELINES; RECTUM; RISK ASSESSMENT; UNNECESSARY PROCEDURES;

EID: 33748616584     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000231754.35340.fa     Document Type: Article

References (12)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16:481-488.
2. National Health and Medical Research Council. Guidelines for the prevention, early detection and management of Colorectal Cancer. Canberra, 1999.
3. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-1471.
4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-1477.
5. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004; 126:1674-1680.
6. Crotta S, Castiglione G, Grazzini G, Valle F, Mosconi S, Rosset R. Feasibility study of colorectal cancer screening by immunochemical faecal occult blood testing: results in a northern Italian community. Eur J Gastroenterol Hepatol 2004; 16:33-37.
7. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, et al. European code against cancer and scientific justification: third version (2003). Ann Oncol 2003; 14:973-1005.
8. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328:1365-1371.
9. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343:1603-1607.
10. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Gastrointestinal consortium panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124:544-560.
11. Worthley DL, Cole SR, Mehaffey S, Roosa NM, Smith A, Turnbull D, et al. Participant satisfaction with fecal occult blood test screening for colorectal cancer. J Gastroenterol Hepatol (in press).
12. Bampton PA, Sandford JJ, Cole SR, Smith A, Morcom J, Cadd B, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut 2005; 54:803-806.